交易 Taysha Gene Therapies Inc - TSHA 差價合約

交易條件

• 類型: 差價合約
• 點差: 0.05
• 長倉隔夜倉息調整: -0.02157%
• 短倉隔夜倉息調整: -0.00065%
• 隔夜倉息調整時間: 21:00 (UTC)
• 貨幣: USD
• 最低成交量: 1
• 保證金: 5.00%
• 證券交易所: United States of America
• 交易佣金: 0%
• 保證止損溢價: 1%

主要統計數據

• 前收盤價: 4.59
• 開倉: 4.65
• 1 年變化: 170.35%
• 日區間: 4.35 - 4.65

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.